Fixed Duration Therapy News Today

Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK inhibitor exposure and the process of clonal selection.

Richard Furman, MD, outlines his strategy for addressing BTK inhibitor intolerance in CLL patients, underscoring the significance of BTK inhibitors in CLL treatment and advocating for transitioning to an alternative BTK inhibitor rather than completely discontinuing the class in cases of drug intolerance.

Oncology experts discuss findings from ELEVATE-RR and outline key considerations for combination with acalabrutinib plus obinutuzumab.

Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.

Experts discuss FDA-approved therapies for DLBCL (diffuse large B cell lymphoma) treatment, including formulations, efficacy profiles, administration impact, patient preferences, and institutional implications.

Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.